GlassScriptPhysician profile
Teresa B Cheney
NPI 1144239104
$3,922.38
in general payments reported to CMS, 2019-2025
40 companies · $62.66 in 2025
The $62.66 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $866 · 2022: $1,593 · 2023: $846 · 2024: $555 · 2025: $62.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.10 | 2021-2025 | |
| Lilly USA, LLC | $321.16 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $283.44 | 2021-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.91 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $236.70 | 2022-2024 | Farxiga, Airsupra |
| Amgen INC. | $228.96 | 2021-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $199.08 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.11 | 2021-2023 | |
| Pfizer INC. | $128.50 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $118.53 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sanofi-Aventis U.S. LLC | $113.16 | 2021-2022 | |
| Glaxosmithkline, LLC. | $105.56 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $102.44 | 2021-2023 | Livalo, Seglentis |
| Boston Scientific Corporation | $98.81 | 2022-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Tris Pharma INC | $95.69 | 2022-2023 | Dyanavel Xr |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Cheney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.